clinical trial · NCT07441642
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy Secondary to Age-related Macular DegenerationFWY003Placebo
brief summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
started
Mar 9, 2026
primary completion
Aug 21, 2029
completion
Aug 22, 2029
last updated
May 12, 2026
detailed description
This study is designed as a randomized, multi-center, double-masked, prospective study to characterize the dose response relationship, efficacy and safety of FWY003.
official title
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol